JAPAN-SAKE-PR-SECRETARIA
Japan Sake and Shochu Makers Association
(hereafter, “JSS") concluded a partnership agreement with the Association de la Sommellerie Internationale
(hereafter, “ASI”) in May this year.
JSS exchanged greetings at the ASI general assembly held at the “Nagoya Marriott Associa Hotel” in Japan on July 5 and 6, and joined the welcome dinner held the night before. There they had the opportunity to meet and greet representatives of sommelier associations from 22 countries who were visiting Japan. Welcome dinner cuisine was paired with wine and six varieties of Japanese sake.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719005658/en/
ASI members were invited to a two-day excursion organized by Mie Sake Brewers Association on July 7 and 8. Participants had the valuable opportunity to tour sake breweries in Mie Prefecture, visit the Ise Grand Shrine that is known for its historical links to sake, and explore the rich history and techniques used to make dashi soup stock at katsuobushi (bonito flakes) production plants.
A sake tasting and discussion event with the member breweries of the Mie Sake Brewers Association, followed by the International Sake Conference in Mie
, were held in the evening of July 7 at the “Shima Kanko Hotel,” which attracted worldwide attention in 2016 as the venue for the G7 ISE-SHIMA SUMMIT. A panel discussion led by six panelists including ASI Chairman Wouters covered topics like the potential of Japanese sake as well as international initiatives being planned by JSS.
Representatives from sommelier associations around the world provided a broad range of feedback on how sake could be paired with various styles of cuisines, with many expressing that they would like to try sake with their own country’s culinary specialties.
The reception featured an eight-course meal fusing French cuisine with dashi-inspired flavors and paired with eight local brands of sake, in an ensemble featuring Mie’s three local specialties—ingredients, dashi and sake. This level of hospitality proved to be a source of amazement and inspiration for the leading international sommeliers who had the chance to savor the flavors provided.
The chairs of the Belgian, Serbian, Spanish, and Mexican sommelier associations expressed their desire to work with JSS and schedule sake master classes in the near feature, thus demonstrating the considerable interest that sommeliers have developed for sake.
Looking forward, JSS will coordinate efforts with ASI by providing sake tasting and seminars at events organized by ASI.
Japan Sake and Shochu Makers Association SNS links are as follows.
FB: https://www.facebook.com/japansakeshochu
IG: https://www.instagram.com/japansakeshochu_en/
YouTube: https://www.youtube.com/user/JapanSakeOfficial
Twitter: https://twitter.com/jss_sake_en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005658/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
